The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. (13th July 2018)

• Record Type: Journal Article
• Authors: Verhoef, Lise M; Selten, Ellen M H; Vriezekolk, Johanna E; de Jong, Alphons J L; van den Hoogen, Frank H J; den Broeder, Alfons A; Hulscher, Marlies E
• Is Part Of: Rheumatology. Volume 57:Number 11(2018)
• Page Start: 1947
• Page End: 1955
• Publication Date: 2018-07-13
• Subjects: rheumatoid arthritis -- DMARDs (biologic) -- patient perspective; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/key205
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: The aim of this study was to identify the factors that play a role for patients with RA when considering dose reduction (i.e. gradual tapering until discontinuation) of biological DMARDs (bDMARDs), and to determine their relative importance. Methods: A mixed methods design was used in which we identified influencing factors by performing semi-structured interviews and ranked these factors using a Maximum Difference Scaling questionnaire. Also, we looked at the influence of several patient characteristics on this ranking. Results: For sub study 1 and 2, 22 and 192 patients with RA were included, respectively, in the analyses. Thirty factors were identified from the interviews—characterized into nine themes—and appraised in the questionnaire. Most respondents had a positive attitude towards bDMARD dose reduction. The study showed that patients are concerned that dose reduction will lead to a disease flare that affects their daily life (pain, function). It is important for them to know that it is possible to increase the dose if (further) reduction fails and that the bDMARD will be effective again. Patients value the opinion of their rheumatologist, and being involved in the decision to start tapering is highly ranked as well. The most important factors were consistent between different groups of patients. Conclusion: The results from this study facilitate implementation of bDMARD dose reduction; they inform care providers on what is important for patients and provide a basis for shared decision making.